Aarti Pharmalabs Q4FY26 Investor Presentation Released; FY27 Capex Outlook Similar to FY26
Aarti Pharmalabs released its Q4 FY26 Investor Presentation. Standalone FY26 revenue was ₹17,976 million, with EBITDA at ₹4,061 million. Consolidated FY26 revenue was ₹18,194 million, with EBITDA at ₹4,024 million. The company targets 15-18% Revenue & EBITDA CAGR over the next 3-4 years. FY26 Capex was ~₹400 crore, with a similar outlook for FY27.
The investor presentation provides a comprehensive overview of the company's performance and future plans, including financial highlights, strategic initiatives, and capex. While positive, it doesn't announce any immediate groundbreaking new orders or significant financial shifts that would warrant a 'HIGH' impact.
The company presented a detailed investor presentation highlighting strong product portfolios, regulatory approvals, and future growth strategies. Financials indicate stable revenue and EBITDA, with positive outlook for future growth and capex plans.
Aarti Pharmalabs Limited has released its Investor Presentation for Q4 FY26. The presentation highlights the company's strong position in the pharmaceutical sector, with over 220 products, 63 patents filed, and a global market share of 15-20% in Xanthine derivatives.
The company has a significant manufacturing presence with 7 units, including 3 USFDA-approved facilities, and holds 60 US DMF and 44 CEP approvals. Aarti Pharmalabs is a leading small molecule CDMO/CMO player in India, focusing on regulatory-driven operations and novel chemistries.
Financially, for FY26, the company reported standalone operational revenue of ₹17,976 million and EBITDA of ₹4,061 million, with an EBITDA margin of 22.59%. On a consolidated basis, operational revenue for FY26 was ₹18,194 million with EBITDA of ₹4,024 million and an EBITDA margin of 22.12%. The company also provided a future outlook, targeting a 15-18% Revenue and EBITDA CAGR over the next 3-4 years on a standalone basis. Capex for FY26 reached approximately ₹400 crore, with a similar outlook for FY27. The company is initiating R&D investment in FY27 towards Peptides & Oligonucleotides (TIDES) to expand its portfolio capabilities. A dedicated block for a specific CDMO project at Atali is planned for groundbreaking in FY27, with a one-year completion target.
What to do with a filing like this
Aarti Pharmalabs Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarti Pharmalabs Limited. Read the original for the full detail.